BriaCell Therapeutics (FRA:8BT0) Price-to-Operating-Cash-Flow : (As of Jun. 28, 2025)

View and export this data going back to 2015. Start your Free Trial

What is BriaCell Therapeutics Price-to-Operating-Cash-Flow?

As of today (2025-06-28), BriaCell Therapeutics's share price is €2.585. BriaCell Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Apr. 2025 was €-10.54. Hence, BriaCell Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for BriaCell Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

FRA:8BT0's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.75
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

BriaCell Therapeutics's Cash Flow from Operations per share for the three months ended in Apr. 2025 was €-1.71. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Apr. 2025 was €-10.54.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 2.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 22.40% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 14.90% per year.

During the past 13 years, BriaCell Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 51.80% per year. The lowest was -34.50% per year. And the median was 9.80% per year.

BriaCell Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for BriaCell Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Price-to-Operating-Cash-Flow Chart

BriaCell Therapeutics Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

BriaCell Therapeutics Quarterly Data
	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BriaCell Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, BriaCell Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BriaCell Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

BriaCell Therapeutics Price-to-Operating-Cash-Flow Calculation

BriaCell Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	2.585	/	-10.541
	=

BriaCell Therapeutics's Share Price of today is €2.585.
BriaCell Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Apr. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.54.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

BriaCell Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (FRA:8BT0) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

BCTX:USA BCT:Canada

Address

235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

BriaCell Therapeutics Headlines

No Headlines